Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Hikma Pharmaceuticals Plc (HKMPF : OTC)

• Company Description    Hikma Pharmaceuticals PLC develops, manufactures and markets pharmaceutical products. Its brand portfolio includes branded, injectables and generic. Branded segment offers dosage forms and strengths in the anti-infective, cardiovascular, diabetes, central nervous system, oncology and respiratory. Injectables segment offers dosage for CNS, controlled substances, anti-infective, cardiovascular and oncology in form of liquid, semi-liquid and powdered form. Generics segment offers dosage for therapeutic including analgesic, anti-infective, anti-inflammatory, cardiovascular, CNS, respiratory and hormonal. Hikma Pharmaceuticals PLC is based in London, the United Kingdom. Number of Employees: 9,500

• Price / Volume Information    Yesterday's Closing Price: $20.94 Daily Weekly Monthly 20 Day Moving Average: 573 shares Shares Outstanding: 221.89 (millions) Market Capitalization: $4,646.30 (millions) Beta: 0.60 52 Week High: $28.92 52 Week Low: $19.67 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -1.90% -1.73% 12 Week -16.94% -18.28% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 1 New Burlington Place - London,X0 W1S 2HR GBR ph: 44-20-7399-2760 fax: 44-0-20-7399-2761 investors@hikma.uk.com http://www.hikma.com

• General Corporate Information    Officers Said Darwazah - Executive Chairman and Chief Executive Officer Mazen Darwazah - Executive Vice Chairman Khalid Nabilsi - Chief Financial Officer Bassam Kanaan - Executive Vice President Hussein Arkhagha - Chief Counsel and Company Secretary Peer Information Hikma Pharmaceuticals Plc (GSAC) Hikma Pharmaceuticals Plc (CASI) Hikma Pharmaceuticals Plc (ALCD.) Hikma Pharmaceuticals Plc (OMNN) Hikma Pharmaceuticals Plc (CGPI.) Hikma Pharmaceuticals Plc (CATX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: G4576K104 SIC: 8880 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: 02/25/26 Share - Related Items Shares Outstanding: 221.89 Most Recent Split Date: (:1) Beta: 0.60 Market Capitalization: $4,646.30 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 3.44% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.72 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 02/25/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 1.82 Price/Cash Flow: 9.39 Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 12/31/25 - - 09/30/25 - - 06/30/25 - - ROA 12/31/25 - - 09/30/25 - - 06/30/25 - - Current Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 1.24 Quick Ratio 12/31/25 - - 09/30/25 - - 06/30/25 - 0.72 Operating Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Net Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Pre-Tax Margin 12/31/25 - - 09/30/25 - - 06/30/25 - - Book Value 12/31/25 - - 09/30/25 - - 06/30/25 - 11.50 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - - 06/30/25 - 0.33 Debt-to-Capital 12/31/25 - - 09/30/25 - - 06/30/25 - 24.82

Powered by Zacks Investment Research ©